Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

THC, PROT.OB, BRD, & RPC: Brigus Gold Corp. Announces C$50 Million "Bought Deal" Financing



Tenet Healthcare Corp. (NYSE: THC)

Tenet Healthcare Corp. announced on September 27, 2010 that Lake Pointe Health Network has appointed Eric Evans as its chief executive officer, effective Sept. 20. The network is located in Rowlett, Texas, and includes Lake Pointe Medical Center, a 112-bed acute care hospital, seven outpatient centers and four physician clinics.

Tenet Healthcare Corporation, an investor-owned health care services company, operates general hospitals and related health care facilities. The company's general hospitals offer acute care services, radiology services, and respiratory therapy services, as well as operate operating and recovery rooms, and clinical laboratories and pharmacies. It also provides intensive care, critical care and/or coronary care units, and physical therapy; orthopedic, oncology, and outpatient services; tertiary care services, such as open-heart surgery, neonatal intensive care, and neuroscience; quaternary care in areas, including heart, lung, liver, and kidney transplants; gamma-knife brain surgery; cyberknife surgery for tumors and lesions in the brain, lung, neck, and spine; and bone marrow transplants.


Proteonomix Inc (OTC BB: PROT.OB)

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix that has recently opened its retail web site,, and begun accepting pre-orders for its anti-aging skin care products. StromaCel, Inc.'s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix's operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (”PRTMI“) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.

PROTEONOMIX, INC., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the Proteonomix, Inc. investment opportunity to institutional investors.

Scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). In addition, Mr. Cohen will discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.

The recent contract calls for the joint venture partner to invest $5 million on or before September 10, 2010 in a Joint Venture company, XGEN Medical LLC. (”XGen”), a Nevis Island limited liability company. For additional details about the joint venture agreement, please refer to the August 17, 2010 press release.


“Proteonomix has made great strides recently,” stated Mr. Cohen, “and we have been contacted by several European entities that have requested additional information about our proprietary stem cell activities. In recognition of the interest in Europe and the potential for additional joint venture agreements in various European countries, we recognize that it is propitious to meet with a number of the European institutional investors both to educate them on the intrinsic value of Proteonomix shares and garner interest in strategic relationships.”

PROT, a biotechnology company, engages in the development of stem cell therapies primarily for the treatment of diabetes and cardiac therapy, as well as offers cosmeceutical products. The stem cell therapy involves the introduction of healthy new stem cells to repair and replace damaged or lost cells. PROT offers product for the treatment of anti-aging and damaged skin.

Provision for the Distribution of Proteoderm, Proteonomix, Inc.'s new Anti-aging line of skin care products (

Additionally, the agreement calls for XGen, the joint venture, to market and distribute Proteoderm, including the Matrix NC-138 anti-aging products.

You should watch this company, as their product is the type that is in demand at lease in the western culture. Make a decision by yourself!

More about PROT at:


Brigus Gold Corp (AMEX: BRD)

Brigus Gold Corp is pleased to announce on September 28, 2010 that it has entered into an agreement with a syndicate of investment dealers, whereby the Underwriters have agreed to: (i) purchase 30,000,000 units of Brigus at a price of C$1.50 per Unit for gross proceeds to the Company of C$45,000,000, and (ii) offer for sale on a guaranteed agency basis, up to 2,941,177 common shares designated as flow-through shares for purposes of the Income Tax Act (Canada), at a price of C$1.70 per Flow-Through Share for gross proceeds to the Company of up to C$5,000,000. Each Unit will consist of one common share and one quarter of one common share purchase warrant, with each Warrant entitling the holder to acquire one Common Share at a price of C$2.19 expiring November 19, 2014. The Flow-Through Shares and the Units will be publicly offered by way of short form prospectus to purchasers resident in each of the provinces and territories of Canada, excluding Quebec.


Radient Pharmaceuticals Corporation (AMEX: RPC)

Radient Pharmaceuticals Corporation a US-based company specializing in the research, development, and international commercialization of In Vitro Diagnostic (IVD) cancer tests, announced on September 28, 2010 that it has entered into an exclusive 5-year full-service distribution agreement with Phu Gia Trading Co. Ltd. to expand the Company's Onko-Sure™ IVD cancer test into the Vietnam, Laos, and Cambodia healthcare markets.
Phu Gia has committed to purchase a minimum of 2,425 Onko-Sure™ kits over the duration of the agreement. Phu Gia Trading Co. Ltd. will represent RPC while obtaining regulatory clearances and providing marketing, sales, and distribution services for Onko-Sure in diagnostic centers and clinical labs throughout the designated territory. Marketing, sales and distribution services include developing product localization strategies; representing Radient Pharmaceuticals and its Onko-Sure IVD cancer test at relevant healthcare conferences and events; and ensuring all relevant product marketing materials are available in local languages. The Phu Gia customer service team will also be responsible for responding to customer inquiries and technical questions. Phu Gia will work directly with the Vietnam Ministry of Health and other government officials to secure approvals and regulatory clearances.









Sign-Up For Free Stock Alerts At


business Card 3



Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (OTCPK:CRWE) has received twenty thousand dollars in cash and twenty thousand dollars in free trading share from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (OTCPK:PROT)


Disclosure: No positions